From: Childhood Liver Cancer Treatment (PDQ®)
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Table 4. Outcomes for Hepatoblastoma Multicenter Trialsa
| Study | Chemotherapy Regimen | Number of Patients | Outcomes |
|---|---|---|---|
| INT0098 (CCG/POG) 1989–1992 | C5V vs. CDDP/DOXO | Stage I/II: 50 | 4-Year EFS/OS: |
| I/II = 88%/100% vs. 96%/96% | |||
| Stage III: 83 | III = 60%/68% vs. 68%/71% | ||
| Stage IV: 40 | IV = 14%/33% vs. 37%/42% | ||
| P9645 (COG)b 1999–2002 | C5V vs. CDDP/CARBO | Stage I/II: Pending publication | 1-Year EFS: |
| I/II: Pending publication | |||
| Stage III: 38 | III/IV: C5V = 51%; CDDP/CARBO = 37% | ||
| Stage IV: 50 | |||
| HB 94 (GPOH) 1994–1997 | I/II: IFOS/CDDP/DOXO | Stage I: 27 | 4-Year EFS/OS: |
| I = 89%/96% | |||
| Stage II: 3 | II = 100%/100% | ||
| III/IV: IFOS/CDDP/DOXO + VP/CARBO | Stage III: 25 | III = 68%/76% | |
| Stage IV: 14 | IV = 21%/36% | ||
| HB 99 (GPOH) 1999–2004 | SR: IPA | SR: 58 | 3-Year EFS/OS: |
| SR = 90%/88% | |||
| HR: CARBO/VP16 | HR: 42 | HR = 52%/55% | |
| SIOPEL-2 1994–1998 | SR: PLADO | PRETEXT I: 6 | 3-Year EFS/OS: |
| SR: 73%/91% | |||
| PRETEXT II: 36 | |||
| PRETEXT III: 25 | |||
| HR: CDDP/CARBO/DOXO | PRETEXT IV: 21 | HR: IV = 48%/61% | |
| Metastases: 25 | HR: metastases = 36%/44% | ||
| SIOPEL-3 1998–2006 | SR: CDDP vs. PLADO | SR: PRETEXT I: 18 | 3-Year EFS/OS: |
| SR: CDDP = 83%/95%; PLADO = 85%/93% | |||
| PRETEXT II: 133 | |||
| PRETEXT III: 104 | |||
| HR: SUPERPLADO | HR: PRETEXT IV: 74 | HR: Overall = 65%/69% | |
| VPE+: 70 | |||
| Metastases: 70 | Metastases = 57%/63% | ||
| AFP <100 ng/mL: 12 | |||
| SIOPEL-4 2005–2009 | HR: Block A: Weekly; CDDP/3 weekly DOXO; Block B: CARBO/DOXO | PRETEXT I: 2 | 3-Year EFS/OS: |
| All HR = 76%/83% | |||
| PRETEXT II: 17 | |||
| PRETEXT III: 27 | |||
| PRETEXT IV: 16 | HR: IV = 75%/88% | ||
| Metastases: 39 | HR: Metastases = 77%/79% | ||
| JPLT-1 1991–1999 | I/II: CDDP(30)/THP-DOXO | Stage I: 9 | 5-Year EFS/OS: |
| I = NR/100% | |||
| Stage II: 32 | II = NR/76% | ||
| III/IV: CDDP(60)/THP-DOXO | Stage IIIa: 48 | IIIa = NR/50% | |
| Stage IIIb: 25 | IIIb = NR/64% | ||
| Stage IV: 20 | IV = NR/77% | ||
| JPLT-2 1999–2010 | I: Low-dose CDDP-pirarubicin | PRETEXT I–IV: 212 | 5-Year EFS/OS: |
| I = NR/100% | |||
| II–IV: CITA | II = NR/89% | ||
| III = NR/93% | |||
| IV = NR/63% | |||
| Metastases: High dose chemotherapy + stem cell transplant | Metastases = 32% |
AFP = alpha-fetoprotein; C5V = cisplatin, 5-fluorouracil (5FU), and vincristine; CARBO = carboplatin; CCG = Children’s Cancer Group; CDDP = cisplatin; CITA = pirarubicin-cisplatin; COG = Children's Oncology Group; DOXO = doxorubicin; EFS = event-free survival; GPOH = Gesellschaft für Pädiatrische Onkologie und Hämatologie (Society for Paediatric Oncology and Haematology); HR = high risk; IFOS = ifosfamide; IPA = ifosfamide, cisplatin, and doxorubicin; JPLT = Japanese Study Group for Pediatric Liver Tumor; NR = not reported; OS = overall survival; PLADO = cisplatin and doxorubicin; POG = Pediatric Oncology Group; PRETEXT = PRE-Treatment EXTent of disease; SIOPEL = International Childhood Liver Tumors Strategy Group; SR = standard risk; SUPERPLADO = cisplatin, doxorubicin, and carboplatin; THP = tetrahydropyranyl-adriamycin (pirarubicin); VP = vinorelbine and cisplatin; VPE+ = venous, portal, and extrahepatic involvement; VP16 = etoposide.
bStudy closed early because of inferior results in the CDDP/CARBO arm.